Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-3031 in R/R Malignancies (Lymphomas and BTC)
NCT03999658Phase 2Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Mar 2023
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of danburstotug in Extranodal NK/T-cell lymphoma (ENKTL), peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL) and 1 more (4 arms), sponsored by Sorrento Therapeutics. Primary endpoint: Objective Response Rate at 24 months. Planned start Mar 2023; status: withdrawn.
02
Drugs
danburstotug
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)peripheral T-cell lymphoma (PTCL)diffuse large B-cell lymphoma (DLBCL)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03999658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03999658.